Association between vitamin D receptor polymorphisms and prostate cancer risk in a Taiwanese population

被引:56
作者
Huang, SP
Chou, YH
Chang, WSW
Wu, MT
Chen, YY
Yu, CC
Wu, TT
Lee, YH
Huang, JK
Wu, WJ
Huang, CH
机构
[1] Kaohsiung Med Univ, Grad Inst Occupat Safety & Hlth, Kaohsiung 807, Taiwan
[2] Kaohsiung Med Univ, Dept Urol, Kaohsiung, Taiwan
[3] Natl Hlth Res Inst, Presidents Lab, Taipei, Taiwan
[4] Kaohsiung Vet Gen Hosp, Div Urol, Dept Surg, Kaohsiung, Taiwan
[5] Chi Mei Med Ctr, Dept Urol, Tainan, Taiwan
关键词
prostate cancer; vitamin D receptor; genetic polymorphisms;
D O I
10.1016/j.canlet.2003.12.006
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Recent molecular epidemiological studies have shown that the inherited polymorphisms of VDR gene may be linked to prostate cancer risk and its aggressive phenotypes. However, the findings remain inconclusive. In this study, we investigated the association of the BsmI, ApaI and TaqI polymorphisms of VDR gene with prostate cancer risk in a Taiwanese population. In total, 160 prostate cancer patients and 205 age-matched male controls were studied between December 2000 and February 2003. No significant associations were found between the ApaI and TaqI polymorphisms and the risk of prostate cancer. However, the control group was found to have a significantly higher frequency of the BsmI `BB' and `Bb' genotypes (15.6%) than prostate cancer patients (8.1%). After adjustment for age, patients with Bsm I `BB' or `Bb' genotypes were associated with a twofold decreased risk (OR = 0.50; 95%CI = 0.25-0.98; P = 0.045) for developing prostate cancer than those with `bb' genotypes. This effect was particularly significant among men below the median age of 72 years (P = 0.017). Moreover, stronger associations were found in the advanced stages (T3/T4/N1/M1) and poorly differentiated disease (Gleason score greater than or equal to 7) (`BB' and `Bb' vs `bb': OR = 0.25; 95%CI = 0.07-0.83; P = 0.024 and OR = 0.25; 95%CI = 0.07-0.85; P = 0.026, respectively). Our findings suggest that the VDR BsmI polymorphism may play a significant role in the development of prostate cancer. (C) 2004 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:69 / 77
页数:9
相关论文
共 29 条
[1]
Blazer DG, 2000, MOL CARCINOGEN, V27, P18
[2]
CERRO LC, 1999, HUM GENET, V105, P281
[3]
Chokkalingam AP, 2001, CANCER RES, V61, P4333
[4]
*DEP HLT REP CHIN, 2001, HLTH STAT
[5]
Vitamin D receptor gene polymorphism in Japanese patients with prostate cancer [J].
Furuya, Y ;
Akakura, K ;
Masai, M ;
Ito, H .
ENDOCRINE JOURNAL, 1999, 46 (03) :467-470
[6]
GETENBERG RH, 1997, UROLOGY, V50, P999
[7]
PREDICTION OF PROGNOSIS FOR PROSTATIC ADENOCARCINOMA BY COMBINED HISTOLOGICAL GRADING AND CLINICAL STAGING [J].
GLEASON, DF ;
MELLINGE.GT .
JOURNAL OF UROLOGY, 1974, 111 (01) :58-64
[8]
Treatment of early recurrent prostate cancer with 1,25-dihydroxyvitamin D3 (calcitriol) [J].
Gross, C ;
Stamey, T ;
Hancock, S ;
Feldman, D .
JOURNAL OF UROLOGY, 1998, 159 (06) :2035-2039
[9]
Vitamin D receptor gene polymorphism and prostate cancer risk [J].
Gsur, A ;
Madersbacher, S ;
Haidinger, G ;
Schatzl, G ;
Marberger, M ;
Vutuc, C ;
Micksche, M .
PROSTATE, 2002, 51 (01) :30-34
[10]
Habuchi T, 2000, CANCER RES, V60, P305